BeStock  
Stocks › ABBV

AbbVie ABBV

US equityMarket cap rank #28
$291.31 +$3.07 (+1.07%)
Market closed · Nov 6, 8:10 pm ET · Last extended-hours $291.31 0.00%
Open$282.27
Prev close$288.24
Day range$281.07 – $291.73
Volume5.04M
Market cap$514.92B
P/E (TTM)50.1
Dividend yield2.34%

Earnings

Average move on report day±3.6%last 16 reports
Closed higher9 of 1656% of the time
Best reaction+6.4%
Worst reaction-8.0%

Stock move on the day after each report

+0.6%2023/Q4-4.6%2024/Q1+3.4%2024/Q2+6.4%2024/Q3+4.7%2024/Q4+3.2%2025/Q1-0.2%2025/Q2-4.5%2025/Q3-3.8%2025/Q4+3.1%2026/Q1-2.5%2026/Q2+1.4%2026/Q3
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q330 Oct 2026Pre Market±4.5%+1.41%Within range
2026/Q231 Jul 2026Pre Market±3.7%-2.51%Within range
2026/Q129 Apr 2026Pre Market±4.2%+3.14%Within range
2025/Q44 Feb 2026Pre Market±4.2%-3.79%Within range
2025/Q331 Oct 2025Pre Market±4.3%-4.45%Bigger than priced
2025/Q231 Jul 2025Pre Market±4.9%-0.15%Within range
2025/Q125 Apr 2025Pre Market±5.9%+3.15%Within range
2024/Q431 Jan 2025Pre Market±5.4%+4.70%Within range
2024/Q330 Oct 2024Pre Market±4.0%+6.36%Bigger than priced
2024/Q225 Jul 2024Pre Market±4.2%+3.38%Within range
2024/Q126 Apr 2024Pre Market±4.9%-4.58%Within range
2023/Q42 Feb 2024Pre Market±4.0%+0.64%Within range
2023/Q327 Oct 2023Pre Market±4.6%-4.32%Within range
2023/Q227 Jul 2023Pre Market±3.6%+4.90%Bigger than priced
2023/Q127 Apr 2023Pre Market±3.0%-7.99%Bigger than priced
2022/Q49 Feb 2023Pre Market±3.5%+2.83%Within range

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Where the revenue comes from

Quarter 2026/Q2

By business line

  • SKYRIZI$5.51B 32.4%
  • Other$2.95B 17.4%
  • RINVOQ$2.53B 14.9%
  • All other$1.11B 6.5%
  • Vraylar$1.07B 6.3%
  • Botox Therapeutic$1.04B 6.1%
  • VENCLEXTA$771.00M 4.5%
  • HUMIRA$756.00M 4.4%
  • Botox Cosmetic$728.00M 4.3%
  • IMBRUVICA$532.00M 3.1%

Fundamentals

Full statements →

Latest reported quarter: Q3, ended Sep 2026

Revenue$17.40B+10.3% YoY
Operating profit$6.48B+41.4% YoY
Net profit$4.22B+2,144.7% YoY
Diluted EPS$2.37+2,270.0% YoY
Free cash flow$3.11B-36.2% YoY
Operating cash flow$3.44B

Revenue, last 8 quarters

$15.1BDec '24$13.3BMar '25$15.4BJun '25$15.8BSep '25$16.6BDec '25$15.0BMar '26$17.0BJun '26$17.4BSep '26

Net profit, last 8 quarters

$-23.0MDec '24$1.3BMar '25$941.0MJun '25$188.0MSep '25$1.8BDec '25$697.0MMar '26$3.6BJun '26$4.2BSep '26

Profitability & balance sheet

Gross margin73.7%
Operating margin36.0%
Net margin15.7%
Liabilities / assets104.4%
Cash & investments$6.57B
Total debt$70.82B
Net cash (debt)-$64.25B

Discussion

No comments yet — be the first to weigh in on ABBV.

Leave a comment

Scroll to Top